Drug Information

Drug (ID: DG02040) and It's Reported Resistant Information

• Name: Anti-PD-1 mAb
• Indication:
  In total 1 Indication(s)
  . .; .
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Lung cancer [ICD-11: 2C25]; [1]
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Lung cancer [ICD-11: 2C25]; [1]

Type(s) of Resistant Mechanism of This Drug

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Lung cancer [ICD-11: 2C25]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Apolipoprotein C-II (APOC2) [1]

• Metabolic Type: Glucose metabolism
• Resistant Disease: Non-small cell lung carcinoma [ICD-11: 2C25.Y]
• Molecule Alteration: Lactylation; K70
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: Breast cancers; Homo Sapiens
• Experiment for Molecule Alteration: Mass spectrometry analysis
• Experiment for Drug Resistance: Western blot assay
• Mechanism Description: Mechanistically, lactate enhances APOC2 lactylation at K70, stabilizing it and resulting in FFA release, regulatory T cell accumulation, immunotherapy resistance, and metastasis.

Key Molecule: Apolipoprotein C-II (APOC2) [1]

• Metabolic Type: Glucose metabolism
• Resistant Disease: Non-small cell lung carcinoma [ICD-11: 2C25.Y]
• Molecule Alteration: Lactylation; K70
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: Gastric cancers; Homo Sapiens
• Experiment for Molecule Alteration: Mass spectrometry analysis
• Experiment for Drug Resistance: Western blot assay
• Mechanism Description: Mechanistically, lactate enhances APOC2 lactylation at K70, stabilizing it and resulting in FFA release, regulatory T cell accumulation, immunotherapy resistance, and metastasis.

Key Molecule: Apolipoprotein C-II (APOC2) [1]

• Metabolic Type: Glucose metabolism
• Resistant Disease: Non-small cell lung carcinoma [ICD-11: 2C25.Y]
• Molecule Alteration: Lactylation; K70
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: Flag-tagged APOC2-K70R mice; Mice
• Experiment for Molecule Alteration: Mass spectrometry analysis
• Experiment for Drug Resistance: Tumor growth assay
• Mechanism Description: Mechanistically, lactate enhances APOC2 lactylation at K70, stabilizing it and resulting in FFA release, regulatory T cell accumulation, immunotherapy resistance, and metastasis.

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Apolipoprotein C-II (APOC2) [1]

• Metabolic Type: Glucose metabolism
• Sensitive Disease: Non-small cell lung carcinoma [ICD-11: 2C25.Y]
• Molecule Alteration: Lactylation; K70
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: Flag-tagged APOC2-WT mice; Mice
• Experiment for Molecule Alteration: Mass spectrometry analysis
• Experiment for Drug Resistance: Tumor growth assay
• Mechanism Description: Mechanistically, lactate enhances APOC2 lactylation at K70, stabilizing it and resulting in FFA release, regulatory T cell accumulation, immunotherapy resistance, and metastasis.

References

• Ref 1: Lactylated Apolipoprotein C-II Induces Immunotherapy Resistance by Promoting Extracellular Lipolysis. Adv Sci (Weinh). 2024 Oct;11(38):e2406333.